Subscribe
shutterstock_2081827810_rafapress-1
rafapress / Shutterstock.com
17 January 2023FeaturesBig PharmaAzadeh Vahdat

Why Novartis lost its treatment dispute with Teva

In a patent revocation and infringement counterclaim action between Teva and Novartis, His Honour Judge Richard Hacon found, in a decision handed down on November 10 2022, lack of inventive step with respect to two Novartis formulation patents ( EP 2,964,202 and EP 3,124,018)

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Is there a step between ‘inventive’ and ‘nonobviousness’?
12 September 2023   Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Is there a step between ‘inventive’ and ‘nonobviousness’?
12 September 2023   Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Big Pharma
Is there a step between ‘inventive’ and ‘nonobviousness’?
12 September 2023   Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.
Big Pharma
Novartis ‘abused’ discovery process for Zolgensma patent
23 May 2023   Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

Sandoz lands reduced antitrust award of $70m
Teva faces $500m fine for antitrust breaches over MS drug
Pfizer infringed haemophilia therapy patent, says court
Big Pharma counsel embrace AI but data and legal risks loom
MSN scores win in battle with Novartis over heart drug generic
HR, lobbying and business strategy…all in a day’s work for today’s counsel
LSPN Fall: Gilead GC shares top drafting tips
LSPN Fall: Why Big Pharma is facing 'a balancing act'